Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs. This study evaluated the impact of the bisphosphonates FDA safety communication on the utilization of osteoporosi...

Full description

Bibliographic Details

Published in:	Saudi Pharmaceutical Journal
Main Authors:	Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio
Format:	Article
Language:	English
Published:	Springer 2018-02-01
Subjects:	Medicaid Osteoporosis Bisphosphonate US food and drug admiration Regulatory warning Utilization
Online Access:	http://www.sciencedirect.com/science/article/pii/S131901641730213X